药明合联2025年中期策略会速递-ADC赛道景气,全球双厂战略推进

华泰证券
Jun 06, 2025

6月4日药明合联出席了我们组织的2025年中期策略会,会上公司指出当前ADC赛道热度持续攀升,2024年报显示在手订单与项目数量储备均持续高速增长,产能端国内及海外生产设施建设正有序推进。我们重申公司在全球产业链地位稳固、业绩持续兑现能力强劲,维持“买入”。ADC行业发展东风正劲商业化及后期临床生产需求攀升:1)德达博妥单抗、Teliso-V分别在25年1月和5月获FDA批准上市,新一代ADC获批...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10